Skip to main content
Medical Reference · Condition Monograph

Chronic Myeloid Leukemia

만성골수성백혈병

A blood cancer in which white blood cells increase abnormally in the bone marrow. A specific genetic abnormality (the Philadelphia chromosome) has been identified as the cause, making it a representative disease whose course has been greatly improved by targeted therapy.

History

Chronic myeloid leukemia (CML) appeared in the medical literature from the mid-19th century as "a disease in which white blood cells increase abnormally and the spleen becomes enlarged." At that time, microscope technology and blood testing methods were just developing, so the very fact that white blood cells became excessively numerous in a patient's blood was a major discovery. Early on, it was sometimes mistaken for an inflammatory disease such as an infection, but over time understanding shifted to "a neoplastic disease caused by the breakdown of order in the blood cells produced in the bone marrow."

Later, as cytogenetics developed in the mid-20th century, it became known that a characteristic chromosomal change was repeatedly observed in the cancer cells of CML patients. The most important turning point was the discovery that a specific chromosomal abnormality, called the Philadelphia chromosome, is found in almost all cases of CML. This is often cited as a representative example showing that "cancer is not simply a mass of unknown cause" but can be directly linked to changes in the genetic material inside cells.

In terms of treatment, anticancer drugs, radiation therapy, and immunomodulatory treatments such as interferon were used in the past, but their limitations in effectiveness and side effects were clear. With the emergence of targeted therapies in the 2000s, the situation changed greatly, and tyrosine kinase inhibitors (TKIs) became the center of CML treatment. The core trend in the history of CML treatment is the change from "a fatal chronic leukemia" to something closer to "a well-manageable chronic disease."

Causes

In most cases, the "direct cause" of CML is not an external cause such as infection or lifestyle, but a specific gene rearrangement that occurs in the stem cells that produce blood cells in the bone marrow. However, why this change occurs in particular people usually cannot be clearly explained. As with many cancers, rather than pinning it down to "one single cause," it is more realistic to understand that random errors at the cellular level and various environmental factors may overlap.

The risk factor known with relative certainty so far is exposure to high doses of radiation. For example, there are reports that the risk of CML increased in groups exposed to very high levels of radiation in large-scale radiation accidents or in certain situations. However, it is excessive to interpret exposure at the level of ordinary medical imaging (e.g., plain X-rays) as directly causing CML.

Many people worry about "heredity," but CML is usually not a disease that is inherited from parents to children. This is because the chromosomal change found in CML is not a change present from birth in every cell of the body, but a change acquired later in specific cells of the bone marrow. Therefore, CML is difficult to explain by family history alone, and in most cases it does not recur within families.

Genetic Epidemiology

CML is unique in that it is "a cancer with a relatively clear genetic abnormality." In most patients, a translocation occurs in which chromosomes 9 and 22 swap places, and as a result the BCR gene and the ABL1 gene join to create an abnormal gene called BCR-ABL1. This change is central to the diagnosis of CML and to the assessment of treatment response, and it can be called "the molecular marker that makes CML what it is."

From an epidemiological perspective, this genetic feature does not appear only in particular ethnic groups or regions. Similar forms of the BCR-ABL1 change are confirmed in most CML patients in many countries around the world. However, the "detailed form (transcript type)" of BCR-ABL1 can vary slightly from patient to patient, and these differences can be linked to which standards are used in testing and which indicators are used to evaluate treatment response.

As treatment continues over a long time, additional gene mutations related to drug resistance may arise in some patients. In such cases, it becomes difficult to continue using the same TKI, and it is necessary to switch to a different class of drug or adjust the treatment strategy. It is best to understand the genetic epidemiology of CML as including not only "the features at initial diagnosis" but also "the changes that arise during treatment." From the general public's point of view, it is enough to remember that "the genetic signal confirmed by testing greatly determines the direction of treatment."

General Epidemiology

CML is a type of chronic leukemia found relatively commonly in adults. Its proportion among all leukemias varies by country and statistical method, but it accounts for a meaningful share of adult leukemias. It is generally diagnosed most often after middle age, and its incidence tends to increase with age. It can occur in both men and women, and the sex difference is reported to be small or only slight.

Recently, as more people have blood tests (complete blood counts) regularly during health checkups, there are many cases in which an increase in white blood cells is discovered incidentally and diagnosed even though there are almost no symptoms. This is largely not because the disease has suddenly increased but "because the methods of detecting it have improved."

As treatment outcomes have improved, the increase in the number of people living with CML is also an important epidemiological change. In the past, the disease often worsened within a few years after diagnosis, but now, with consistent appropriate targeted therapy, the disease can be suppressed for a long time, so the "number of people living with the disease" may show an increasing pattern.

Pathogenesis

The core pathogenesis of CML is the "always-on growth signal" produced by the abnormal gene called BCR-ABL1. In normal cells, growth signals turn on only when needed and turn off when not needed. However, BCR-ABL1 abnormally activates an enzyme called tyrosine kinase (TK), continuously sending signals that make the cell keep dividing and surviving.

As a result, granulocytes (a type of white blood cell) are produced excessively in the bone marrow and pour out into the blood. In the early stage, a characteristic feature is that "myeloid cells at multiple stages," from immature cells to mature cells, increase together. As the disease progresses over time, immature cells (blasts) increase rapidly and normal blood formation is suppressed, which can increase the risk of anemia, bleeding, and infection.

CML can progress through the stages of chronic phase → accelerated phase → blast phase. In the chronic phase, the disease progresses relatively slowly and is often well controlled with medication, but when it moves into the accelerated or blast phase, it can worsen rapidly like acute leukemia, making treatment more difficult. The accumulation of additional genetic abnormalities is known to be involved in this process of progression.

Symptoms

Surprisingly, it is common for CML to have "no symptoms at first." It is diagnosed, for example, when a blood test at a health checkup shows high white blood cells and further tests are done. When there are symptoms, they usually begin with a feeling of whole-body exhaustion and loss of energy. This can be related to fatigue caused by anemia, a chronic inflammatory response, or the abnormal functioning of blood cell production in the body.

Another common symptom is reduced food intake or a feeling of bloating. Because the spleen often becomes enlarged in CML (splenomegaly), there may be discomfort in the upper left abdomen or early satiety, feeling full quickly after eating only a little. Heavy sweating at night (night sweats), recurrent low-grade fever, or unexplained weight loss may also appear. These symptoms are also called "B symptoms" and can be a sign that disease activity has increased.

Rarely, when the white blood cell count becomes very high and a hyperviscosity state develops in which the blood becomes thick, symptoms such as headache, dizziness, and blurred vision may occur. A bleeding tendency, such as easy bruising, nosebleeds, or gum bleeding, may also appear, and this can be related to abnormalities in platelet count or platelet function.

Signs

"Signs" refer to objective findings identified on examination or testing. The most typical sign in CML is an increase in white blood cells on a blood test. It is not simply that the number is high; it may be accompanied by a left shift, in which immature granulocytes are also seen on the peripheral blood smear. In addition, when an increase in basophils (basophilia) and an increase in eosinophils are observed together, CML is more strongly suspected.

On physical examination, splenomegaly is an important sign. The physician palpates the spleen by feeling the abdomen, or confirms it with ultrasound or CT. In some cases, the liver may also become enlarged. As anemia progresses, the patient may look pale, and if there are platelet abnormalities, petechial bleeding or bruises may be seen on the skin.

Above all, the "key sign" of CML is the identification of BCR-ABL1 on molecular testing. This is not a sign visible to the eye, but because it is decisive in confirming CML and setting treatment goals, it is clinically the most important objective finding.

Screening

Currently, there is generally no special screening test recommended for the entire population for CML. This is because CML is relatively rare and the benefit of screening for CML alone in an asymptomatic state is limited. In reality, however, the most common "de facto screening" is the complete blood count (CBC) performed at regular health checkups.

Because a CBC can check white blood cell, red blood cell (hemoglobin), and platelet counts at once, it helps detect abnormalities such as increased white blood cells or anemia early. If the white blood cell count is persistently high on a CBC, basophils are increased, or immature cells are seen on the peripheral blood smear, further evaluation is needed.

For people who may be at relatively higher risk, such as those with a history of high-dose radiation exposure or those who have had other blood disorders, having regular blood tests after consulting a physician can help with early detection. For the general public, however, "not missing abnormal findings at regular checkups" is a more realistic approach than a "special test."

Diagnosis

The diagnosis of CML usually proceeds step by step. The first step is a blood test (CBC) and a peripheral blood smear. If findings such as increased white blood cells, left shift, and basophilia are seen here, a bone marrow examination (bone marrow aspiration and/or biopsy) is next performed to check whether granulocytic cells are proliferating excessively in the bone marrow. The bone marrow examination is also important for determining the phase of the disease (chronic phase, accelerated phase, blast phase).

To confirm the diagnosis, BCR-ABL1 must be identified. Methods include confirming the t(9;22) translocation by chromosome testing (karyotyping) or confirming the gene rearrangement by fluorescence in situ hybridization (FISH). The amount of BCR-ABL1 can also be measured by quantitative reverse transcription polymerase chain reaction (RT-PCR) testing of blood or bone marrow, which is central not only to diagnosis but also to tracking treatment response.

After diagnosis, the risk of the disease is assessed to plan the treatment strategy. There are methods that calculate a risk score by combining spleen size, platelet count, age, the proportion of immature cells in the blood, and other factors. These scores serve as a reference for deciding "whether to treat more aggressively," "which drug to choose first," and "how often to perform follow-up tests."

Treatment

The center of CML treatment is the tyrosine kinase inhibitor (TKI). This drug works by inhibiting the action of the abnormal tyrosine kinase produced by BCR-ABL1, cutting off the growth signal of the cancer cells. Typically, a strategy is used that starts with imatinib and adjusts to second- or third-generation drugs depending on the treatment response or the presence of resistance.

Treatment is often started even when there are almost no symptoms. This is because controlling CML well early increases the likelihood of maintaining the chronic phase for a long time. During treatment, blood tests are used to check whether the counts stabilize, and RT-PCR is used at regular intervals to track how much the BCR-ABL1 level has fallen. The goal is to achieve a deep level of reduction called a "molecular response." Side effects differ by drug, but they may include swelling, muscle pain, skin rash, gastrointestinal symptoms, and elevated liver enzymes, so regular monitoring is needed.

In some patients, allogeneic hematopoietic stem cell transplantation (HSCT) may be considered. This is a treatment from which a cure can be expected, but because it carries treatment-related risks and a burden of complications, it is not applied to every patient. It is mainly decided by a specialist after a comprehensive assessment in cases with strong drug resistance, progression to the blast phase, or certain other situations. In dangerous situations in which white blood cells rise sharply, measures such as intravenous fluids, uric acid management, and sometimes leukapheresis may be used in combination.

Prognosis

The prognosis of CML has improved greatly over the past 20 or so years. Before targeted therapies were introduced, the disease often progressed over time to the accelerated or blast phase and became life-threatening. Now, however, in many patients the disease can be suppressed for a long time with TKI treatment, and there are also reports of cases managed so that life expectancy is not very different from that of the general population.

Factors that determine prognosis include the phase of the disease at diagnosis (whether it is the chronic phase or already the accelerated or blast phase), the speed of response to initial treatment, whether the medication can be taken consistently, and whether resistance mutations develop. Whether the BCR-ABL1 level decreases quickly beyond a certain threshold during treatment and whether a deep molecular response is maintained are important indicators.

In some patients, if a deep response is maintained for a sufficiently long time, "treatment-free remission," in which treatment is stopped and the patient is observed under specialist management, may be attempted. However, this is not possible for everyone, and it requires strict conditions and frequent follow-up molecular testing. From the general public's point of view, it is good to understand that "most cases are well controlled with medication, but regular follow-up molecular testing is very important."

Prevention

Because CML mostly arises as an acquired condition and the cause is often unclear, it is difficult to present a "definite method of prevention." However, avoiding high-dose radiation exposure, one of the known risk factors, may help. Realistically, the most important thing in daily life is to reduce unnecessary radiation exposure and to receive necessary tests at an appropriate level after consulting with medical staff.

Although evidence of a strong direct link to lifestyle is limited, overall health care has great significance during treatment. Regular exercise, a balanced diet, not smoking, moderate drinking, and adequate sleep support immune function and cardiovascular health and can also help in maintaining drug treatment over the long term.

If "complete prevention" is difficult, it is realistic to focus on "early detection." It is advisable to detect CBC abnormalities early through regular health checkups and not to put off testing when the white blood cell count remains high or when there are symptoms such as unexplained fatigue, abdominal discomfort suggesting splenomegaly, night sweats, and weight loss. This is because CML tends to be easier to manage the earlier it is detected and treatment is started in the chronic phase.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.